New two-drug combo aims to wipe out HER2 breast cancer before surgery
NCT ID NCT06747338
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal is to see if the new combination works better at eliminating cancer before surgery. About 520 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KN026 (a bispecific antibody) combined with HB1801 (a chemotherapy drug)
- What this could lead to
- If successful, this could offer a more effective pre-surgery treatment option for people with HER2-positive breast cancer, potentially improving the chance of eliminating all cancer before surgery.
- What could go wrong
- This is an early-phase comparison; the new combination may not be more effective than the current standard and could have unexpected side effects. Results are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trials Information Group
Shanghai, China